<DOC>
	<DOC>NCT00125723</DOC>
	<brief_summary>The purpose of the study is to assess the impact of first and subsequent cycle pegfilgrastim on neutropenia events (such as hospitalizations, dose reductions and delays) in patients receiving myelosuppressive chemotherapy.</brief_summary>
	<brief_title>FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Pathologically confirmed diagnosis of the following malignancies: breast, nonHodgkin's lymphoma (NHL), Hodgkin's disease, ovarian, colorectal, lung or other Planned administration of a new myelosuppressive every 14 (q14), q21, or q28 day chemotherapy Written informed consent for participation in the study before any studyspecific procedures are performed, including screening and registration Exclusion Criteria: Planned concomitant therapeutic radiation Diagnosis of acute or chronic leukemia or myelodysplastic syndrome Prior stemcell transplantation (includes bonemarrow transplantation) Medical diagnosis of chronic neutropenia of any cause not related to cancer Current cytotoxic, biologic, or immunologic therapy for unrelated conditions Subject has active infection requiring treatment Known HIVpositive subjects Subject of childbearing potential is evidently pregnant (e.g., positive HCG test) or is breast feeding Subject of childbearing potential is not using adequate contraceptive precautions Known sensitivity to E. coli derived drug products (e.g., filgrastim, HUMULIN速 insulin, Lasparaginase, HUMATROPE速 growth hormone, INTRON A速) Any psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with study protocol procedures Subject is currently enrolled in, or has not yet completed at least 30 days since ending another device or drug trial(s) or is receiving, or plans to receive, other investigational agent(s) not approved by the Food and Drug Administration (FDA)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase 4 Clinical Trial</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Neulasta速</keyword>
	<keyword>Oncology</keyword>
	<keyword>Malignancy</keyword>
</DOC>